TIGIT
38 programs · 38 companies
Programs
38
Companies
38
Active Trials
19
Targeting TIGIT
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | Endometrial CaIPF | |
| MRK-6781 | Merck & Co | Approved | PsA | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | Heart Failure | |
| BNT-5232 | BioNTech | NDA/BLA | ETEpilepsy | |
| ALN-8757 | Alnylam | Preclinical | BCC | |
| Miritinib | Neurocrine | Phase 3 | LNPNH | |
| UTH-9370 | United Therapeutics | NDA/BLA | PsANSCLC | |
| COR-9456 | Corcept | Preclinical | SLEUC | |
| RLA-6817 | Relay Therapeutics | Phase 3 | BCC | |
| KYM-8808 | Kymera | Phase 1/2 | AS | |
| Nidasacituzumab | Day One Bio | Phase 3 | Crohn'sOCD | |
| CGO-2579 | CG Oncology | Approved | Hemophilia ARSV | |
| Lisoinavolisib | Schrodinger | Approved | MesoEpilepsy | |
| Voxavorutinib | Carmot (Roche) | NDA/BLA | NMOSDFabry | |
| CRG-4097 | Cargo Therapeutics | Phase 3 | CeliacOCD | |
| Zenoderotide | Adagene | Phase 1/2 | Ovarian CaCSU | |
| KRO-9986 | Keros Ther | Phase 3 | RSVCKD | |
| Teracilimab | Zevra Therapeutics | Phase 2/3 | FLMM | |
| Ivozasiran | Enochian Bio | Preclinical | ETUC | |
| Suraderotide | Compass Inc | Phase 1 | SchizophreniaADHD | |
| Lirainavolisib | Zenas BioPharma | Preclinical | FTDPsoriasis | |
| Mavutuximab | MedMira | Phase 1 | MMCholangiocarcinoma | |
| Elrasertib | Janux Ther | Phase 3 | NSCLCCTCL | |
| PCV-2362 | Vaxcyte | Phase 1 | PSPMG | |
| Sotocapivasertib | Avrobio | Approved | RSVHCC | |
| Gozezumab | MeiraGTx | Approved | PTSDCSU | |
| Peminesiran | Oncorus (sold) | Phase 1 | EpilepsyObesity | |
| Capimavacamten | Twist Bioscience | Phase 1 | CRCPsoriasis | |
| Terarelsin | Laboratorios Rovi | Phase 1/2 | ADPKDNMOSD | |
| AJA-5085 | Ajanta Pharma | Preclinical | Ewing SarcomaEndometrial Ca | |
| ZYD-981 | Zydus Lifesciences | Preclinical | AsthmaADPKD | |
| PHA-5173 | Pharmaniaga | Phase 3 | LNFSGS | |
| WES-IIT-947 | West China Hosp | Phase 2 | IPF | |
| AII-IIT-879 | AIIMS New Delhi | Preclinical | HS | |
| POL-7277 | Polpharma | Phase 1 | CSUObesity | |
| ZTS-7156 | Zoetis | Preclinical | HNSCCCrohn's | |
| Capifotisoran | Elanco | Approved | Bladder CaCTCL | |
| EWT-9686 | Edgewise Therapeutics | Phase 1 | PAHUrothelial Ca |